Business Wire

Marinus Pharmaceuticals Announces Topline Results from Phase 3 RAISE Trial of IV Ganaxolone in Refractory Status Epilepticus

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced ...
UVA Today

UVA Researchers To Test Ketamine’s Power To Stop Deadly Epilepsy Seizures

University of Virginia Brain Institute and School of Medicine researchers have received an initial $9.3 million award from the National Institutes of Health to determine if the powerful anesthetic ...
News Medical

Drexel University researchers explore effective drug for treating established status epilepticus

Drexel University College of Medicine researchers are conducting an emergency medicine study to find out the most effective drug for treating established status epilepticus -- a life-threatening ...
Morningstar

Natus announces FDA 510(k) clearance for electrographic status epilepticus diagnostic indication in BrainWatch point-of-care EEG solution

MIDDLETON, Wis., Dec. 3, 2025 /PRNewswire/ -- Natus Medical Incorporated announced the electrographic status epilepticus diagnosis capability of its BrainWatch point-of-care EEG solution, featuring ...